158sek
0,8 %
Date:2024-03-01Time:17:29:45Latest report:Q4-2023List:Small CapTicker:KDEV
Market Cap:421 msekEnterprise Value:336 msekNet Sales:2,01 msekEarnings:5,39 msekEmployees:0ISIN:SE0002190926

Ratios

10-year key figure history for Karolinska Development turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Karolinska Development with index and moving average MA50 and MA200.

Stockprice:1,58
MA50:1,69
MA200:1,64
Price/MA200:-4,8 %
RSI (14):37,4
Price/MA50:-8,1 %

Description

Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Holding Companies